Dr Tim Carter has been appointed Chief Executive Officer following the resignation of Neil Butler. Dr Carter, a founder of the company and previously Chief Scientific Officer and inventor of its proprietary piezofilm technology, has more than 30 years experience in clinical diagnostics. He managed the transformation of IP fenced technology into a reduced to practice product format at excellent clinical performance. He is also the co-inventor of the successfully commercialised enhanced chemi-luminescence technology.
Vivacta’s Board has accepted Neil Butler’s resignation and wishes to thank him for his critical contribution in building the company. Neil’s strategic and operational experience and leadership has made it possible for the company to develop, validate and demonstrate its unique patented technology.
The Board also announces the appointment of Oliver Boucher as its Chief Business Officer and member of the Executive Management Team. Mr Boucher will lead the commercialisation of Vivacta’s innovative piezofilm technology which forms the core of a new generation of near-patient diagnostic products achieving very high sensitivity combined with wide dynamic range.
Mr. Boucher brings over 15 years of commercial development and licensing experience to Vivacta, gained both in large and small organisations. Most recently, Oliver was Chief Business Officer at Sigmoid Pharma, an oral drug delivery company. Before that, he spent six years as Vice-President of commercial development at Trigen, the European cardiovascular drug development specialist. Prior to entering the small company sector, Mr Boucher spent seven years in senior positions within the business development group of multinational pharmaceutical giant, GSK.
"The appointments of Tim Carter and Oliver Boucher signal the company’s readiness to enter strategic and commercial partnerships” said Rolf Classon, non-executive Chairman of the Board.
Vivacta today also announced the intention by its four major shareholders Viking, Spark, IDInvest Partners (formerly AGF Private Equity) and HBM shortly to complete a financing round of £4 million.
About Vivacta:
Vivacta Limited is a privately-held, venture capital-backed medical diagnostic company developing proprietary sensors and readers for rapid, point-of-care (PoC) diagnostic testing. The company is applying piezofilm technology to achieve extremely high sensitivity and dynamic range for a new generation of diagnostic products adapted to near-patient testing and has generated an independent intellectual property position comprising over 10 patent families. Piezofilms prepared using Vivacta’s proprietary methods can be made to generate an electric charge in proportion to the amount of analyte (substance to be detected in the blood sample) which binds to the piezofilm sensor. For more information please visit: http://www.vivacta.com
CONTACTS: Oliver Boucher – Chief Business Officer- 0044 1795 419400 Nigel Newton – Finance Director – 0044 1795 419400 Web site: www.vivacta.com
Alex Heeley Account Manager
De Facto Communications
330 High Holborn London WC1V 7QD
Telephone: +44 (0)207 861 3838 Direct: +44 (0)207 861 3043 Fax: +44 (0)207 861 3839
E-mail: A.heeley@defacto.com
www.defacto.com
